netFormulary NHS
North Central London
Joint Formulary
 Search
 Formulary Chapter 9: Nutrition and blood - Full Chapter
09.09  Expand sub section  Unlicensed Medicines / Significant off-label use
Azathioprine
(Haematology)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
AAAAAAAA

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
  • RFL:
    • Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
 
Ciclosporin
(Haematology)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
AAAAAAAA

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
  • RFL:
    • Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
 
Cyclophosphamide tablets
(Haematology)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
  • RFL:
    • Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
 
Danazol
(Haematology)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
AAAAAAAA

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
  • RFL:
    • Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
 
Eculizumab infusion
(Hyperhaemolysis)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
AAAAAAAA

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for 2nd line management of Delayed Haemolytic Transfusion Reactions [DHTRs] hyperhaemolysis in adult Sickle Cell and β-thalassaemia patients who have not responded to IVIG and steroids (pending internal funding approval; JFC July 2019)

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
    • Restricted to haematology. UMC to be informed of each patient. Funding agreed for 1 patient per annum. 
  • WH:
    • Non-formulary
 
Mycophenolate mofetil
(Haematology)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
AAAAAAAA

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
  • RFL:
    • Approved for Immune thrombocytopenia (ITP) and Autoimmune Haemolytic Anaemia (AIHA)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
 
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Homecare
Homecare

Traffic Light Status Information

Status Description

GP - Amber

Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.  

Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.

Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.

  

GP - Red

Medicines which should normally be prescribed by specialists only (hospital only).

For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.

See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf

  

Black

Medicines not recommended for routine use in primary or secondary care.

Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.

  

netFormulary